Difficult divorce
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
PharmaTimes Magazine Archive
Magazine highlights
View more from the latest edition
The gut microbiome – the macro debate
This year pharma began to turn its eye towards the power of the microbiome
Integrated care agenda stimulates seismic change in 2018
The NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma
Biosimilars: recent legal and regulatory developments
The true impact of biosimilars is starting to be felt across the industry
AI is not new
...But this year its impact, and the potential for change, was felt across the pharma industry
2018 patent case highlights
The biggest cases of the past year
The age of personalised medicine is coming
James Huang & Stephen Huang on the groundbreaking technologies that could change precision medicine in the near future
2018 – a slow year for M&A?
The value and volume of deals in H1 were higher than in the full year 2017, but a slow second half puts us a long way off 2015’s records
